Different levels of healing in inflammatory bowel diseases: mucosal, histological, transmural, barrier and complete healing
暂无分享,去创建一个
[1] N. Kapel,et al. Fecal calprotectin for the diagnosis and management of inflammatory bowel diseases. , 2023, Clinical and translational gastroenterology.
[2] G. D'Haens,et al. Upadacitinib Induction and Maintenance Therapy for Crohn's Disease. , 2023, The New England journal of medicine.
[3] A. Shields,et al. A comparative evaluation of the measurement properties of three histological indices of mucosal healing in ulcerative colitis: Geboes Score, Robarts Histopathology Index, and Nancy Index. , 2023, Journal of Crohn's & colitis.
[4] M. Grova,et al. Ustekinumab is a promising option for the treatment of postoperative recurrence of Crohn's disease. , 2023, Journal of gastroenterology and hepatology.
[5] L. Peyrin-Biroulet,et al. Resolving Histological Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes , 2023, Journal of Crohn's & colitis.
[6] E. Louis,et al. In-Depth Assessment of Endoscopic Remission in Inflammatory Bowel Disease Treated by Anti-TNF or Vedolizumab. , 2023, Inflammatory bowel diseases.
[7] M. Silverberg,et al. Vedolizumab for the Treatment of Chronic Pouchitis. , 2023, The New England journal of medicine.
[8] E. Grisan,et al. Artificial Intelligence enabled histological prediction of remission or activity and clinical outcomes in ulcerative colitis. , 2023, Gastroenterology.
[9] B. Sands,et al. Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. , 2023, The lancet. Gastroenterology & hepatology.
[10] B. Verstockt,et al. Patient reported outcomes and disability are associated with histological disease activity in patients with ulcerative colitis: results from the APOLLO study. , 2023, Journal of Crohn's & colitis.
[11] Minhu Chen,et al. Early transmural healing and its predictors assessed by magnetic resonance enterography in patients with Crohn’s disease receiving ustekinumab , 2023, Therapeutic advances in gastroenterology.
[12] E. Peeva,et al. Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study. , 2023, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[13] D. Rubin,et al. Intestinal Ultrasound in the Assessment and Management of Inflammatory Bowel Disease: Is it Ready for Standard Practice? , 2023, Gastroenterology.
[14] M. Byrne,et al. Application of Deep Learning Models to Improve Ulcerative Colitis Endoscopic Disease Activity Scoring Under Multiple Scoring Systems. , 2022, Journal of Crohn's & colitis.
[15] Q. Lu,et al. Trans-Compartmental Regulation of Tight Junction Barrier Function , 2022, Tissue barriers.
[16] M. Neurath,et al. Intestinal barrier healing is superior to endoscopic and histologic remission for predicting major adverse outcomes in IBD: the prospective ERIca trial. , 2022, Gastroenterology.
[17] S. Vermeire,et al. Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial. , 2022, The lancet. Gastroenterology & hepatology.
[18] M. Regueiro,et al. The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium , 2022, The American journal of gastroenterology.
[19] M. Neurath,et al. Endocytoscopy for assessing histologic inflammation in ulcerative colitis: development and prospective validation of the ELECT score (ErLangen Endocytoscopy in ColiTis). , 2022, Gastrointestinal endoscopy.
[20] B. Christensen. Histologic Healing in Inflammatory Bowel Disease. , 2022, Gastroenterology & hepatology.
[21] A. Bitton,et al. Impact of Endoscopic and Histologic Activity on Disease Relapse in Ulcerative Colitis , 2022, The American journal of gastroenterology.
[22] Kyeong Ok Kim. Endoscopic activity in inflammatory bowel disease: clinical significance and application in practice , 2022, Clinical endoscopy.
[23] J. Marshall,et al. The Performance of the Rutgeerts Score, SES-CD, and MM-SES-CD for Prediction of Postoperative Clinical Recurrence in Crohn's Disease. , 2022, Inflammatory bowel diseases.
[24] Fraser Cummings,et al. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial , 2022, The Lancet.
[25] Qiuhe Lu,et al. Local barriers configure systemic communications between the host and microbiota , 2022, Science.
[26] S. Ishihara,et al. Low Fecal Calprotectin Predicts Histological Healing in Patients with Ulcerative Colitis with Endoscopic Remission and Leads to Prolonged Clinical Remission. , 2022, Inflammatory bowel diseases.
[27] S. Vermeire,et al. Real-world endoscopic and histologic outcomes are correlated with ustekinumab exposure in patients with ulcerative colitis. , 2022, Journal of Crohn's & colitis.
[28] M. Dubinsky,et al. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials , 2022, The Lancet.
[29] M. Dubinsky,et al. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial , 2022, The Lancet.
[30] S. Vermeire,et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials , 2022, The Lancet.
[31] M. Neurath,et al. Impact of Epithelial Cell Shedding on Intestinal Homeostasis , 2022, International journal of molecular sciences.
[32] P. Gibson,et al. Toward transmural healing: Sonographic healing is associated with improved long‐term outcomes in patients with Crohn’s disease , 2022, Alimentary pharmacology & therapeutics.
[33] G. Latella,et al. Systematic review and meta-analysis: the advantage of endoscopic Mayo score 0 over 1 in patients with ulcerative colitis , 2022, BMC Gastroenterology.
[34] M. Iacucci,et al. Endoscopy and histology in inflammatory bowel diseases patients: Complementary or alternatives?-Author's reply. , 2022, United European gastroenterology journal.
[35] E. Grisan,et al. PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificial intelligence system , 2022, Gut.
[36] D. Rubin,et al. Guselkumab for the treatment of Crohn's disease: Induction results from the Phase 2 GALAXI-1 study. , 2022, Gastroenterology.
[37] S. Vermeire,et al. Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial. , 2022, The lancet. Gastroenterology & hepatology.
[38] G. Fiorino,et al. Histological Scores in Patients with Inflammatory Bowel Diseases: The State of the Art , 2022, Journal of clinical medicine.
[39] G. Fiorino,et al. Endoscopy and histology in inflammatory bowel diseases patients: Complementary or alternatives? , 2022, United European gastroenterology journal.
[40] H. Yoon,et al. Histologic Evaluation Using the Robarts Histopathology Index in Patients With Ulcerative Colitis in Deep Remission and the Association of Histologic Remission With Risk of Relapse. , 2022, Inflammatory bowel diseases.
[41] T. Grimstad,et al. Histologic healing and factors associated with complete remission following conventional treatment in ulcerative colitis , 2022, Therapeutic advances in gastroenterology.
[42] J. Panés,et al. The Efficacy and Safety of Guselkumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 2b QUASAR Study Results Through Week 12. , 2022, Gastroenterology & hepatology.
[43] A. Ananthakrishnan,et al. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. , 2021, The lancet. Gastroenterology & hepatology.
[44] P. Higgins,et al. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients with Crohn's Disease. , 2021, Gastroenterology.
[45] Teck Kiang Tan,et al. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. , 2021, The lancet. Gastroenterology & hepatology.
[46] J. Garssen,et al. Epithelial integrity, junctional complexes, and biomarkers associated with intestinal functions , 2021, Tissue barriers.
[47] M. Dubinsky,et al. Defining Transabdominal Intestinal Ultrasound Treatment Response and Remission in Inflammatory Bowel Disease: Systematic Review and Expert Consensus Statement , 2021, Journal of Crohn's & colitis.
[48] S. Hanauer,et al. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. , 2021, The New England journal of medicine.
[49] M. Ferrante,et al. Assessment of Endoscopic Disease Activity in Ulcerative Colitis: Is Simplicity the Ultimate Sophistication? , 2021, Inflammatory Intestinal Diseases.
[50] A. Desideri,et al. GATA6 deficiency leads to epithelial barrier dysfunction and enhances susceptibility to gut inflammation. , 2021, Journal of Crohn's & colitis.
[51] Fachao Zhi,et al. An IRF1-dependent pathway of TNFα-induced shedding in intestinal epithelial cells. , 2021, Journal of Crohn's & colitis.
[52] M. Kamm,et al. Endoscopic Prediction of Crohn's Disease Postoperative Recurrence. , 2021, Inflammatory bowel diseases.
[53] L. Peyrin-Biroulet,et al. Transmural healing as a therapeutic goal in Crohn's disease: a systematic review. , 2021, The lancet. Gastroenterology & hepatology.
[54] S. Vermeire,et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial , 2021, The Lancet.
[55] John A. Williams,et al. Ultra-high Magnification Endocytoscopy and Molecular Markers for Defining Endoscopic and Histologic Remission in Ulcerative Colitis—An Exploratory Study to Define Deep Remission , 2021, Inflammatory bowel diseases.
[56] T. Voiosu,et al. Surrogate markers of mucosal healing in inflammatory bowel disease: A systematic review , 2021, World journal of gastroenterology.
[57] H. Tilg,et al. Validation of the ‘Inflammatory Bowel Disease—Distribution, Chronicity, Activity [IBD-DCA] Score’ for Ulcerative Colitis and Crohn´s Disease , 2021, Journal of Crohn's & colitis.
[58] J. Marshall,et al. Predicting endoscopic remission in Crohn’s disease by the modified multiplier SES-CD (MM-SES-CD) , 2021, Gut.
[59] M. Neurath,et al. Intestinal Mucosal Wound Healing and Barrier Integrity in IBD–Crosstalk and Trafficking of Cellular Players , 2021, Frontiers in Medicine.
[60] A. Saftoiu,et al. Deep Learning Algorithm for the Confirmation of Mucosal Healing in Crohn's Disease, Based on Confocal Laser Endomicroscopy Images. , 2021, Journal of gastrointestinal and liver diseases : JGLD.
[61] S. Vermeire,et al. Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study , 2021, Journal of Crohn's & colitis.
[62] C. Dai,et al. Optimal Range of Fecal Calprotectin for Predicting Mucosal Healing in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis , 2021, Visceral Medicine.
[63] Qingli Zhu,et al. Comparison of transmural healing and mucosal healing as predictors of positive long-term outcomes in Crohn’s disease , 2021, Therapeutic advances in gastroenterology.
[64] R. Kiesslich,et al. An international multicenter real-life prospective study of electronic chromoendoscopy score PICaSSO in Ulcerative Colitis. , 2020, Gastroenterology.
[65] L. Peyrin-Biroulet,et al. Probe-based confocal laser endomicroscopy for in vivo assessment of histological healing in ulcerative colitis: development and validation of the ENHANCE index. , 2020, Journal of Crohn's & colitis.
[66] T. Okumura,et al. The endoscopic diagnosis of mucosal healing and deep remission in inflammatory bowel disease , 2020, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society.
[67] A. Amiot,et al. Evolution of endoscopic lesions in steroid-refractory acute severe ulcerative colitis responding to infliximab or cyclosporine. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[68] A. Variola,et al. Role of Ulcerative Colitis Endoscopic Index of Severity (UCEIS) versus Mayo Endoscopic Subscore (MES) in Predicting Patients′ Response to Biological Therapy and the Need for Colectomy , 2020, Digestion.
[69] K. Tokushige,et al. Relationship between mucosal healing by tacrolimus and relapse of refractory ulcerative colitis: a retrospective study , 2020, BMC Gastroenterology.
[70] P. Dulai,et al. Deep Learning Accurately Predicts Endoscopic and Histologic Remission in Ulcerative Colitis - What the Eye Doesn't See, the Artificial Mind Does Actually Know. , 2020, Gastroenterology.
[71] A. Kornbluth. Histologic Healing in Ulcerative Colitis: Benefits. And Risks. Was Voltaire Right? , 2020, Inflammatory bowel diseases.
[72] J. Lewis,et al. Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease. , 2020, Gastroenterology.
[73] T. Hibi,et al. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis. , 2020, Gastroenterology.
[74] R. Bucala,et al. CD74 Signaling Links Inflammation to Intestinal Epithelial Cell Regeneration and Promotes Mucosal Healing , 2020, Cellular and molecular gastroenterology and hepatology.
[75] M. Silverberg,et al. Histological Markers of Clinical Relapse in Endoscopically Quiescent Ulcerative Colitis. , 2019, Inflammatory bowel diseases.
[76] T. Kucharzik,et al. Intestinal ultrasound for monitoring therapeutic response in patients with ulcerative colitis: results from the TRUST&UC study , 2019, Gut.
[77] S. Vermeire,et al. Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients with Ulcerative Colitis. , 2019, Gastroenterology.
[78] P. Rutgeerts,et al. Effects of Ustekinumab on Histologic Disease Activity in Patients with Crohn's Disease. , 2019, Gastroenterology.
[79] S. Targan,et al. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. , 2019, The New England journal of medicine.
[80] B. Sands,et al. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. , 2019, The New England journal of medicine.
[81] Richard Strauss,et al. A simplified definition of histologic improvement in ulcerative colitis and its association with disease outcomes up to 30 weeks from initiation of therapy: Post-hoc analysis of three clinical trials. , 2019, Journal of Crohn's & colitis.
[82] B. Flourié,et al. Usefulness of confocal laser endomicroscopy for predicting postoperative recurrence in patients with Crohn's disease: a pilot study. , 2019, Gastrointestinal endoscopy.
[83] M. Neurath. Targeting immune cell circuits and trafficking in inflammatory bowel disease , 2019, Nature Immunology.
[84] Siddharth Singh,et al. Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials , 2019, The American journal of gastroenterology.
[85] A. Ananthakrishnan,et al. Complete histologic normalisation is associated with reduced risk of relapse among patients with ulcerative colitis in complete endoscopic remission , 2019, Alimentary pharmacology & therapeutics.
[86] N. Caporaso,et al. One‐year clinical outcomes with biologics in Crohn's disease: transmural healing compared with mucosal or no healing , 2019, Alimentary pharmacology & therapeutics.
[87] N. Moreno,et al. Clinical Impact of Sonographic Transmural Healing After Anti-TNF Antibody Treatment in Patients with Crohn’s Disease , 2019, Digestive Diseases and Sciences.
[88] Emmanuel Coron,et al. Quantitative assessment of mucosal architecture using computer-based analysis of confocal laser endomicroscopy in inflammatory bowel diseases. , 2019, Gastrointestinal endoscopy.
[89] Tsuyoshi Ozawa,et al. Novel computer-assisted diagnosis system for endoscopic disease activity in patients with ulcerative colitis. , 2019, Gastrointestinal endoscopy.
[90] K. Mori,et al. Fully automated diagnostic system with artificial intelligence using endocytoscopy to identify the presence of histologic inflammation associated with ulcerative colitis (with video). , 2019, Gastrointestinal endoscopy.
[91] A. Kaser,et al. Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study. , 2018, The lancet. Gastroenterology & hepatology.
[92] P. Rutgeerts,et al. Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease. , 2018, Gastroenterology.
[93] J. Stoker,et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. , 2018, Journal of Crohn's & colitis.
[94] A. Griffiths,et al. Associations Among Mucosal and Transmural Healing and Fecal Level of Calprotectin in Children With Crohn's Disease , 2018, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[95] M. Neurath,et al. I-scan optical enhancement for the in vivo prediction of diminutive colorectal polyp histology: Results from a prospective three-phased multicentre trial , 2018, Endoscopy.
[96] R. Leong,et al. Molecular Pathophysiology of Epithelial Barrier Dysfunction in Inflammatory Bowel Diseases , 2018, Proteomes.
[97] R. Kiesslich,et al. Development and validation of the SIMPLE endoscopic classification of diminutive and small colorectal polyps , 2018, Endoscopy.
[98] M. Neurath,et al. Prediction of clinical outcomes in Crohn's disease by using confocal laser endomicroscopy: results from a prospective multicenter study. , 2017, Gastrointestinal endoscopy.
[99] B. Moum,et al. Fecal Calprotectin: A Reliable Predictor of Mucosal Healing after Treatment for Active Ulcerative Colitis , 2017, Gastroenterology research and practice.
[100] T. Phan,et al. Impaired Intestinal Permeability Contributes to Ongoing Bowel Symptoms in Patients With Inflammatory Bowel Disease and Mucosal Healing. , 2017, Gastroenterology.
[101] P. Rutgeerts,et al. Vedolizumab Induces Long-term Mucosal Healing in Patients With Crohn’s Disease and Ulcerative Colitis , 2017, Journal of Crohn's & colitis.
[102] M. Neurath,et al. Activation of Epithelial Signal Transducer and Activator of Transcription 1 by Interleukin 28 Controls Mucosal Healing in Mice With Colitis and Is Increased in Mucosa of Patients With Inflammatory Bowel Disease. , 2017, Gastroenterology.
[103] B. Feagan,et al. Histologic scoring indices for evaluation of disease activity in ulcerative colitis. , 2017, The Cochrane database of systematic reviews.
[104] Chao Ding,et al. Ulcerative Colitis Endoscopic Index of Severity (UCEIS) versus Mayo Endoscopic Score (MES) in guiding the need for colectomy in patients with acute severe colitis , 2017, Gastroenterology report.
[105] Wolfgang Uter,et al. Multispectral Optoacoustic Tomography for Assessment of Crohn's Disease Activity. , 2017, The New England journal of medicine.
[106] M. Neurath,et al. Mend Your Fences , 2017, Cellular and molecular gastroenterology and hepatology.
[107] H. Ogata,et al. Endocytoscopy can be used to assess histological healing in ulcerative colitis , 2017, Endoscopy.
[108] R. Kiesslich,et al. Advanced endoscopy imaging in inflammatory bowel diseases. , 2017, Gastrointestinal endoscopy.
[109] L. Laine,et al. Histological Disease Activity as a Predictor of Clinical Relapse Among Patients With Ulcerative Colitis: Systematic Review and Meta-Analysis , 2016, The American Journal of Gastroenterology.
[110] M. Dubinsky,et al. Fecal Calprotectin Levels Predict Histological Healing in Ulcerative Colitis , 2016, Inflammatory bowel diseases.
[111] John T. Chang,et al. The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium , 2016, American Journal of Gastroenterology.
[112] P. Higgins,et al. Endoscopic Mucosal Healing Predicts Favorable Clinical Outcomes in Inflammatory Bowel Disease: A Meta-analysis , 2016, Inflammatory bowel diseases.
[113] M. Regueiro,et al. Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. , 2016, Gastroenterology.
[114] D. Morozov,et al. A Pilot Study of Confocal Laser Endomicroscopy to Predict Barrier Dysfunction and Relapse in Pediatric Inflammatory Bowel Disease , 2016, Journal of pediatric gastroenterology and nutrition.
[115] T. Matozaki,et al. Promotion of Intestinal Epithelial Cell Turnover by Commensal Bacteria: Role of Short-Chain Fatty Acids , 2016, PloS one.
[116] S. Vermeire,et al. Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis. , 2016, The New England journal of medicine.
[117] S. Osawa,et al. The Ulcerative Colitis Endoscopic Index of Severity More Accurately Reflects Clinical Outcomes and Long-term Prognosis than the Mayo Endoscopic Score. , 2016, Journal of Crohn's & colitis.
[118] L. Stitt,et al. Development and validation of a histological index for UC , 2015, Gut.
[119] S. Travis,et al. Development and validation of the Nancy histological index for UC , 2015, Gut.
[120] D. Altman,et al. The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS] , 2015, Journal of Crohn's & colitis.
[121] P. Vilmann,et al. Confocal laser endomicroscopy: a novel method for prediction of relapse in Crohn’s disease , 2015, Endoscopy.
[122] J. Mansfield,et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial , 2014, The Lancet.
[123] B. Korelitz,et al. Histological healing favors lower risk of colon carcinoma in extensive ulcerative colitis. , 2014, World journal of gastroenterology.
[124] P. Piselli,et al. Confocal laser endomicroscopy for prediction of disease relapse in ulcerative colitis: a pilot study. , 2014, Journal of Crohn's & colitis.
[125] Wolfgang Uter,et al. In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease , 2014, Nature Medicine.
[126] I. Ordás,et al. Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn's disease. , 2014, Gastroenterology.
[127] P. Rutgeerts,et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. , 2014, Gastroenterology.
[128] A. Amiot,et al. European evidence based consensus for endoscopy in inflammatory bowel disease. , 2013, Journal of Crohn's & colitis.
[129] E. Louis,et al. Serum calprotectin as a biomarker for Crohn's disease. , 2013, Journal of Crohn's & colitis.
[130] H. Ogata,et al. Mucosal healing with oral tacrolimus is associated with favorable medium- and long-term prognosis in steroid-refractory/dependent ulcerative colitis patients. , 2013, Journal of Crohn's & colitis.
[131] D. Rubin,et al. Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[132] P. Rutgeerts,et al. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. , 2013, Gastroenterology.
[133] M F Neurath,et al. New targets for mucosal healing and therapy in inflammatory bowel diseases , 2013, Mucosal Immunology.
[134] Kristin Stephens,et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. , 2013, The New England journal of medicine.
[135] P. Rutgeerts,et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. , 2013, The New England journal of medicine.
[136] N. Caporaso,et al. Transmural Healing Evaluated by Bowel Sonography in Patients with Crohn’s Disease on Maintenance Treatment with Biologics , 2013, Inflammatory bowel diseases.
[137] W. Sandborn,et al. 52-Week Efficacy of Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis Who Failed Corticosteroids and/or Immunosuppressants , 2013, Inflammatory bowel diseases.
[138] S. Travis,et al. Association between the ulcerative colitis endoscopic index of severity (UCEIS) and outcomes in acute severe ulcerative colitis. , 2013, Journal of Crohn's & colitis.
[139] M. Neurath,et al. Endocytoscopy Allows Accurate In Vivo Differentiation of Mucosal Inflammatory Cells in IBD: A Pilot Study , 2013, Inflammatory bowel diseases.
[140] A. Schoepfer,et al. Fecal Calprotectin More Accurately Reflects Endoscopic Activity of Ulcerative Colitis than the Lichtiger Index, C-reactive Protein, Platelets, Hemoglobin, and Blood Leukocytes , 2013, Inflammatory bowel diseases.
[141] M. Neurath,et al. Assessment of Crohn's disease activity by confocal laser endomicroscopy , 2012, Journal of Digestive Endoscopy.
[142] W. Sandborn,et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. , 2012, The New England journal of medicine.
[143] M. Neurath,et al. Mucosal healing in inflammatory bowel diseases: a systematic review , 2012, Gut.
[144] P. Rutgeerts,et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. , 2012, Gastroenterology.
[145] T. Matsui,et al. Double‐blind, placebo‐controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid‐refractory ulcerative colitis , 2012, Inflammatory bowel diseases.
[146] O. Dewit,et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol , 2012, Gut.
[147] G. D'Haens,et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. , 2012, Gastroenterology.
[148] R. Kiesslich,et al. Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease , 2011, Gut.
[149] D. Altman,et al. Translational Gastroenterology , 2011 .
[150] P. Rutgeerts,et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. , 2011, Gastroenterology.
[151] J. Llach,et al. Narrow-band imaging as an alternative to chromoendoscopy for the detection of dysplasia in long-standing inflammatory bowel disease: a prospective, randomized, crossover study. , 2011, Gastrointestinal endoscopy.
[152] Helmut Neumann,et al. Caspase-8 regulates TNF-alpha induced epithelial necroptosis and terminal ileitis , 2011, Nature.
[153] H. Ogata,et al. Correlation between endocytoscopy and conventional histopathology in microstructural features of ulcerative colitis , 2011, Journal of Gastroenterology.
[154] Helmut Neumann,et al. Prospective evaluation of the learning curve of confocal laser endomicroscopy in patients with IBD. , 2011, Histology and histopathology.
[155] V. de Lédinghen,et al. Mucosal healing with methotrexate in Crohn’s disease: a prospective comparative study with azathioprine and infliximab , 2011, Alimentary pharmacology & therapeutics.
[156] Helmut Neumann,et al. New endoscopic approaches in IBD. , 2011, World journal of gastroenterology.
[157] I. Ordás,et al. Colonic Crohn’s disease: value of magnetic resonance colonography for detection and quantification of disease activity , 2010, Abdominal Imaging.
[158] M. Allez,et al. Role of endoscopy in predicting the disease course in inflammatory bowel disease. , 2010, World journal of gastroenterology.
[159] S. Gallus,et al. Are Colonoscopy and Bowel Ultrasound Useful for Assessing Response to Short-Term Therapy and Predicting Disease Outcome of Moderate-to-Severe Forms of Ulcerative Colitis?: A Prospective Study , 2010, The American Journal of Gastroenterology.
[160] P. Rutgeerts,et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.
[161] A. Sapino,et al. Azathioprine, mucosal healing in ulcerative colitis, and the chemoprevention of colitic cancer: a clinical-practice-based forecast. , 2010, Inflammation & allergy drug targets.
[162] P. Rutgeerts,et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. , 2010, Gastroenterology.
[163] P. Rutgeerts,et al. Mucosal healing predicts long‐term outcome of maintenance therapy with infliximab in Crohn's disease , 2009, Inflammatory bowel diseases.
[164] K. Petraki,et al. Azathioprine Is Superior to Budesonide in Achieving and Maintaining Mucosal Healing and Histologic Remission in Steroid‐Dependent Crohn's Disease , 2009, Inflammatory bowel diseases.
[165] K. Thakkar,et al. Repeat Endoscopy Affects Patient Management in Pediatric Inflammatory Bowel Disease , 2009, The American Journal of Gastroenterology.
[166] I. Ordás,et al. Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn’s disease , 2009, Gut.
[167] I. Gorelov,et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial , 2008, Gut.
[168] N. Harpaz,et al. Chromoendoscopy-Targeted Biopsies Are Superior to Standard Colonoscopic Surveillance for Detecting Dysplasia in Inflammatory Bowel Disease Patients: A Prospective Endoscopic Trial , 2008, The American Journal of Gastroenterology.
[169] M. Vos,et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial , 2008, The Lancet.
[170] M. Vatn,et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. , 2007, Gastroenterology.
[171] M. Kamm,et al. MMX Multi Matrix System® mesalazine for the induction of remission in patients with mild‐to‐moderate ulcerative colitis: a combined analysis of two randomized, double‐blind, placebo‐controlled trials , 2007, Alimentary pharmacology & therapeutics.
[172] P. Rutgeerts,et al. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? , 2007, Gut.
[173] M. Bala,et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease , 2006 .
[174] S. Targan,et al. Natalizumab induction and maintenance therapy for Crohn's disease. , 2005, The New England journal of medicine.
[175] G. Porro,et al. A rare cause of diuretic refractory ascites , 2005, Gut.
[176] T. Horiuchi,et al. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. , 2005, Gastroenterology.
[177] C. López-Otín,et al. Differential Expression of Three Matrix Metalloproteinases, MMP-19, MMP-26, and MMP-28, in Normal and Inflamed Intestine and Colon Cancer , 2004, Digestive Diseases and Sciences.
[178] P. Rutgeerts,et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. , 2004, Gastroenterology.
[179] A. Røseth,et al. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease , 2004, Scandinavian journal of gastroenterology.
[180] Bernhard Nafe,et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. , 2003, Gastroenterology.
[181] M. Neurath,et al. Noninvasive assessment of Crohn's disease activity: a comparison of 18F-fluorodeoxyglucose positron emission tomography, hydromagnetic resonance imaging, and granulocyte scintigraphy with labeled antibodies , 2002, American Journal of Gastroenterology.
[182] S. Hanauer,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[183] R. Jian,et al. Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy , 2002, American Journal of Gastroenterology.
[184] L. Mortelmans,et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. , 2001, Gastroenterology.
[185] A. Öst,et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis , 2000, Gut.
[186] V. Dessirier,et al. Transforming Growth Factor-α and Epidermal Growth Factor Receptor in Colonic Mucosa in Active and Inactive Inflammatory Bowel Disease , 2000, Growth factors.
[187] Å. Danielsson,et al. Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. , 1996, Gastroenterology.
[188] T. Kardos,et al. Comparison of cryosurgery and the carbon dioxide laser in mucosal healing. , 1991, International journal of oral and maxillofacial surgery.
[189] S. Riley,et al. Microscopic activity in ulcerative colitis: what does it mean? , 1991, Gut.
[190] P. Rutgeerts,et al. Predictability of the postoperative course of Crohn's disease. , 1990, Gastroenterology.
[191] M. Langer,et al. [Effect of immediate dentures on mucosal healing and bone remodeling]. , 1984, L' Information dentaire.
[192] S. Truelove,et al. Cortisone in Ulcerative Colitis , 1954 .
[193] W. Sandborn,et al. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. , 2017, The New England journal of medicine.
[194] J. E. Domínguez-Muñoz,et al. Evaluation of the Risk of Relapse in Ulcerative Colitis According to the Degree of Mucosal Healing (Mayo 0 vs 1): A Longitudinal Cohort Study. , 2016, Journal of Crohn's & colitis.
[195] P. Rutgeerts,et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. , 2014, Gastroenterology.
[196] A. Zinsmeister,et al. Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[197] L. Peyrin-Biroulet,et al. Clinical implications of mucosal healing for the management of IBD , 2010, Nature Reviews Gastroenterology &Hepatology.
[198] M. Kamm,et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. , 2007, Gastroenterology.
[199] A. Cohen,et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. , 2001, Gastroenterology.
[200] V. Dessirier,et al. Transforming growth factor-alpha and epidermal growth factor receptor in colonic mucosa in active and inactive inflammatory bowel disease. , 2000, Growth factors.
[201] D. Freeman,et al. Early mucosal healing and chronic changes in pony jejunum after various types of strangulation obstruction. , 1988, American journal of veterinary research.
[202] G PLACITELLI,et al. [Ulcerative colitis]. , 1958, La Riforma medica.
[203] S. Truelove,et al. Cortisone in ulcerative colitis; final report on a therapeutic trial. , 1955, British medical journal.